Emergent Biosolutions (NYSE:EBS) Director Sells $144,496.80 in Stock

Emergent Biosolutions Inc. (NYSE:EBS) Director Kathryn Zoon sold 17,202 shares of the firm’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $144,496.80. Following the transaction, the director directly owned 79,941 shares of the company’s stock, valued at approximately $671,504.40. This represents a 17.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Performance

Shares of Emergent Biosolutions stock opened at $9.13 on Thursday. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. Emergent Biosolutions Inc. has a 1 year low of $4.72 and a 1 year high of $14.06. The firm’s 50-day simple moving average is $8.46 and its 200-day simple moving average is $10.30. The firm has a market cap of $471.72 million, a PE ratio of -32.62 and a beta of 2.33.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.46. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.The firm had revenue of $156.10 million during the quarter, compared to analyst estimates of $145.00 million.

Analysts Set New Price Targets

A number of research firms have commented on EBS. HC Wainwright decreased their price objective on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating for the company in a report on Monday, March 9th. Wall Street Zen downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Emergent Biosolutions has a consensus rating of “Hold” and a consensus target price of $12.00.

Institutional Investors Weigh In On Emergent Biosolutions

Several large investors have recently made changes to their positions in the company. Sanctuary Advisors LLC acquired a new position in shares of Emergent Biosolutions during the first quarter worth approximately $508,000. Values First Advisors Inc. increased its position in Emergent Biosolutions by 0.9% in the 1st quarter. Values First Advisors Inc. now owns 307,880 shares of the biopharmaceutical company’s stock valued at $2,555,000 after acquiring an additional 2,834 shares during the period. SG Americas Securities LLC raised its stake in Emergent Biosolutions by 4.6% during the 1st quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company’s stock valued at $352,000 after acquiring an additional 1,865 shares in the last quarter. Evolve Private Wealth LLC acquired a new position in Emergent Biosolutions during the 1st quarter worth $546,000. Finally, Baron Wealth Management LLC grew its stake in shares of Emergent Biosolutions by 40.2% in the first quarter. Baron Wealth Management LLC now owns 15,120 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 4,335 shares in the last quarter. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.